Indomethacin: New polymorphs of an old drug

Molecular Pharmaceutics

Volumn 10, Issue 12, 2013, Pages 4472-4480

  Surwase, Sachin A ^a   Boetker, Johan P ^b   Saville, Dorothy ^a   Boyd, Ben J ^c   Gordon, Keith C ^a   Peltonen, Leena ^d   Strachan, Clare J ^a,d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

amorphous; aqueous suspensions; indomethacin; new polymorphs; solvent mediated crystallization; toxicology study

Indexed keywords

INDOMETACIN;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; PH; PHYSICAL CHEMISTRY; POWDER; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SOLID; SOLID STATE; STRUCTURE ACTIVITY RELATION; SUSPENSION; TEMPERATURE; ULTRAVIOLET SPECTROSCOPY; X RAY POWDER DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; INDOMETHACIN; POWDERS; SUSPENSIONS; TEMPERATURE; WATER; X-RAY DIFFRACTION;

EID: 84889243159     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400299a     Document Type: Article

References (32)

1. Csermely, P.; Korcsmaros, T.; Kiss, H. J.; London, G.; Nussinov, R. Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review Pharmacol. Ther. 2013, 138 (3) 333-408
2. Stegemann, S.; Leveiller, F.; Franchi, D.; de Jong, H.; Lindén, H. When poor solubility becomes an issue: From early stage to proof of concept Eur. J. Pharm. Sci. 2007, 31 (5) 249-261 (Pubitemid 47079001)
3. Di, L.; Fish, P. V.; Mano, T. Bridging solubility between drug discovery and development Drug Discovery Today 2012, 17 (9-10) 486-495
4. Turner, J. R. Drug Discovery. In New Drug Development; Springer: New York, 2010; pp 21-34.
5. Li, P.; Zhao, L. Developing early formulations: Practice and perspective Int. J. Pharmaceutics 2007, 341 (1-2) 1-19 (Pubitemid 47088122)
6. Baird, J. A.; Van Eerdenbrugh, B.; Taylor, L. S. A classification system to assess the crystallization tendency of organic molecules from undercooled melts J. Pharm. Sci. 2010, 99 (9) 3787-3806
7. Engers, D.; Teng, J.; Jimenez-Novoa, J.; Gent, P.; Hossack, S.; Campbell, C.; Thomson, J.; Ivanisevic, I.; Templeton, A.; Byrn, S.; Newman, A. A solid-state approach to enable early development compounds: Selection and animal bioavailability studies of an itraconazole amorphous solid dispersion J. Pharm. Sci. 2010, 99 (9) 3901-3922
8. Neervannan, S. Preclinical formulations for discovery and toxicology: physicochemical challenges Expert Opin. Drug Metab. Toxicol. 2006, 2 (5) 715-731 (Pubitemid 46118317)
9. Hancock, B. C.; Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 1997, 86 (1) 1-12
10. Laitinen, R.; Lobmann, K.; Strachan, C. J.; Grohganz, H.; Rades, T. Emerging trends in the stabilization of amorphous drugs Int. J. Pharmaceutics 2013, 453, 65-79
11. Bhugra, C.; Pikal, M. J. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state J. Pharm. Sci. 2008, 97 (4) 1329-1349
12. Savolainen, M.; Kogermann, K.; Heinz, A.; Aaltonen, J.; Peltonen, L.; Strachan, C.; Yliruusi, J. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy Eur. J. Pharm. Biopharm. 2009, 71 (1) 71-79
13. Wu, T.; Sun, Y.; Li, N.; de Villiers, M. M.; Yu, L. Inhibiting surface crystallization of amorphous Indomethacin by nanocoating Langmuir 2007, 23 (9) 5148-5153 (Pubitemid 46732007)
14. Alonzo, D.; Zhang, G.; Zhou, D.; Gao, Y.; Taylor, L. Understanding the behavior of amorphous pharmaceutical systems during dissolution Pharm. Res. 2010, 27 (4) 608-618
15. Greco, K.; Bogner, R. Crystallization of amorphous Indomethacin during dissolution: effect of processing and annealing Mol. Pharmaceutics 2010, 7 (5) 1406-1418
16. Andronis, V.; Yoshioka, M.; Zografi, G. Effects of sorbed water on the crystallization of indomethacin from the amorphous state J. Pharm. Sci. 1997, 86 (3) 346-351
17. Andronis, V.; Zografi, G. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state J. Non-Cryst. Solids 2000, 271 (3) 236-248
18. Hancock, B. C.; Shamblin, S. L.; Zografi, G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures Pharm. Res. 1995, 12 (6) 799-806
19. Borka, L. The polymorphism of indomethacin. New modifications, their melting behaviour and solubility Acta Pharm. Suec. 1974, 11, 295-303
20. Lin, S. Y. Isolation and solid-state characteristics of a new crystal form of indomethacin J. Pharm. Sci. 1992, 81 (6) 572-576
21. Savolainen, M.; Heinz, A.; Strachan, C.; Gordon, K. C.; Yliruusi, J.; Rades, T.; Sandler, N. Screening for differences in the amorphous state of indomethacin using multivariate visualization Eur. J. Pharm. Sci. 2007, 30 (2) 113-123 (Pubitemid 46149278)
22. Crowley, K. J.; Zografi, G. Cryogenic grinding of indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability J. Pharm. Sci. 2002, 91 (2) 492-507 (Pubitemid 34139812)
23. Rumondor, A. C. F.; Marsac, P. J.; Stanford, L. A.; Taylor, L. S. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture Mol. Pharmaceutics 2009, 6 (5) 1492-1505
24. Heinz, A.; Savolainen, M.; Rades, T.; Strachan, C. J. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy Eur. J. Pharm. Sci. 2007, 32 (3) 182-192 (Pubitemid 47532710)
25. Strachan, C. J.; Rades, T.; Gordon, K. C. A theoretical and spectroscopic study of γ-crystalline and amorphous indometacin J. Pharm. Pharmacol. 2007, 59 (2) 261-269 (Pubitemid 46203064)
26. Threlfall, T. Structural and thermodynamic explanations of Ostwald's rule Org. Process Res. Dev. 2003, 7 (6) 1017-1027 (Pubitemid 37543832)
27. Aceves-Hernandez, J. M.; Nicolás-Vázquez, I.; Aceves, F. J.; Hinojosa-Torres, J.; Paz, M.; Castaño, V. M. Indomethacin polymorphs: Experimental and conformational analysis J. Pharm. Sci. 2009, 98 (7) 2448-2463
28. Aubrey-Medendorp, C.; Swadley, M.; Li, T. The polymorphism of indomethacin: An analysis by density functional theory calculations Pharm. Res. 2008, 25 (4) 953-959 (Pubitemid 351661824)
29. Taylor, L. S.; Zografi, G. Spectroscopic characterization of interactions between PVP and Indomethacin in amorphous molecular dispersions Pharm. Res. 1997, 14 (12) 1691-1698 (Pubitemid 28062912)
30. Heinz, A.; Strachan, C.; Gordon, K.; Rades, T., Insight into different solid-state forms of indomethacin using vibrational spectroscopy, multivariate analysis, and quantum chemical modeling. In American Association of Pharmaceutical Scientists; Georgia World Congress Center, Atlanta, 2008; pp AAPS2008-001461.
31. Priemel, P. A.; Grohganz, H.; Gordon, K. C.; Rades, T.; Strachan, C. J. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin Eur. J. Pharm. Biopharm. 2012, 82 (1) 187-193
32. Nicolaï, B.; Céolin, R.; Rietveld, I. Polymorphism and solvation of indomethacin J. Therm. Anal. Calorim. 2010, 102 (1) 211-216